lincocin 300 mg/ml sol. inj. i.v. ser. préremplie
pfizer sa-nv - chlorhydrate de lincomycine - eq. lincomycine 300 mg/ml - solution injectable - 300 mg/ml - chlorhydrate de lincomycine - lincomycin
lincocin pro injectione 100 mg/ml sol. inj. i.m./i.v. flac.
zoetis belgium sa-nv - chlorhydrate de lincomycine - eq. lincomycine 100 mg/ml - solution injectable - 100 mg/ml - lincomycine 100 mg/ml - lincomycin - chien; chat; porc
inclunox solution
sandoz canada incorporated - Énoxaparine sodique - solution - 30mg - Énoxaparine sodique 30mg - heparins
inclunox solution
sandoz canada incorporated - Énoxaparine sodique - solution - 40mg - Énoxaparine sodique 40mg - heparins
inclunox solution
sandoz canada incorporated - Énoxaparine sodique - solution - 60mg - Énoxaparine sodique 60mg - heparins
inclunox solution
sandoz canada incorporated - Énoxaparine sodique - solution - 80mg - Énoxaparine sodique 80mg - heparins
inclunox solution
sandoz canada incorporated - Énoxaparine sodique - solution - 100mg - Énoxaparine sodique 100mg - heparins
inclunox hp solution
sandoz canada incorporated - Énoxaparine sodique - solution - 120mg - Énoxaparine sodique 120mg - heparins
inclunox hp solution
sandoz canada incorporated - Énoxaparine sodique - solution - 150mg - Énoxaparine sodique 150mg - heparins
cancidas (previously caspofungin msd)
merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimycotiques pour une utilisation systémique - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.